BioSpace News Archive

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone , Anixa’s Chief Development Officer, has been invited to present at the 8th Annual CAR-TCR Summit being held from August 29 – September 1, 2023 in Boston, MA.

CNS Pharmaceuticals, Inc. today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company’s novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX) today announced its financial results for the three months ended June 30, 2023, and other recent developments.

Vaso Corporation (“Vaso”) (OTCQB:VASO) today reported its operating results for the three months ended June 30, 2023.

AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability

Boehringer Ingelheim announced that SENVELGO®, a revolutionary new treatment for cats with diabetes, has been approved by the U.S. Food and Drug Administration.

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.

Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

CohBar, Inc. reported its financial results and highlights for the second quarter ended June 30, 2023.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent business highlights.